Literature DB >> 16890780

Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).

William T Shearer, Jaime G DeVille, Pearl M Samson, John H Moye, Courtney V Fletcher, Joseph A Church, Hans M L Spiegel, Paul Palumbo, Terence Fenton, M Elizabeth Smith, Bobbie Graham, Joyce M Kraimer, William C Olson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16890780     DOI： 10.1016/j.jaci.2006.03.028

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  4 in total

1.  Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children.

Authors:  Courtney V Fletcher; Jaime G DeVille; Pearl M Samson; John H Moye; Joseph A Church; Hans M L Spiegel; Paul Palumbo; Terence Fenton; M Elizabeth Smith; Bobbie Graham; Joyce M Kraimer; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2007-03       Impact factor: 10.793

Review 2.  Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.

Authors:  Lun Li; Jin Hui Tian; KeHu Yang; Peng Zhang; Wen Qin Jia
Journal:  Cochrane Database Syst Rev       Date:  2014-07-26

Review 3.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

Review 4.  CCR5 monoclonal antibodies for HIV-1 therapy.

Authors:  William C Olson; Jeffrey M Jacobson
Journal:  Curr Opin HIV AIDS       Date:  2009-03       Impact factor: 4.283
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.